Keywords: Bayer, Regorafenib, Rare sarcome, GIST, Dana-Farber Cancer Institute

Bayer's regorafenib overcomes resistance in patients with rare sarcoma

Article | 22 November 2012

Print This

A new targeted drug - German drug major Bayer’s (BAYN: DE) regorafenib (trade name Stivarga) - demonstrated ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in